CVKD Cadrenal Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1937993 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.8%
TTM EPS YoY57.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-358.3%
ROA-267.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets16.0%
Debt / equity0.00x
Current ratio6.26x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $224,576 | $705,151 | $771,508 | $666,323 | $688,465 | $1.08M | $1.67M | $1.54M |
| SG&A expense | $1.04M | $2.63M | $1.74M | $2.40M | $2.04M | $2.66M | $2.25M | $2.74M |
| Operating income | -$1.27M | -$3.34M | -$2.51M | -$3.07M | -$2.73M | -$3.73M | -$3.93M | -$4.28M |
| Net income | -$1.25M | -$3.32M | -$2.50M | -$3.04M | -$2.69M | -$3.67M | -$3.85M | -$4.19M |
| EBITDA | -$1.26M | -$3.34M | -$2.51M | -$3.06M | -$2.73M | -$3.73M | -$3.92M | -$4.28M |
| EPS (basic) | -0.31 | -1.14 | -1.04 | — | -1.31 | -1.87 | -2.09 | — |
| EPS (diluted) | -0.31 | -1.14 | -1.04 | — | -1.31 | -1.87 | -2.09 | — |
| Dividends declared per share | — | — | — | 0.00 | 0.00 | 0.00 | 16.50 | — |
| Weighted avg. shares (diluted) | 4.06M | 2.91M | 2.41M | — | 2.04M | 1.96M | 1.84M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.06M | $2.39M | $2.31M | $4.01M | $3.86M | $5.57M | $7.34M | $10.02M |
| Current assets | $3.45M | $5.58M | $2.86M | $4.32M | $4.08M | $5.97M | $7.94M | $10.11M |
| PP&E, net | $2,274 | $2,675 | $4,619 | $5,174 | $5,729 | $4,277 | $4,678 | $6,944 |
| Total assets | $3.46M | $5.59M | $2.86M | $4.33M | $4.09M | $5.98M | $7.95M | $10.12M |
| Current liabilities | $551,336 | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M |
| Total liabilities | $551,336 | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M |
| Shareholders' equity | $2.90M | $4.09M | $1.80M | $2.74M | $2.73M | $4.30M | $6.11M | $7.44M |
| Shares outstanding | 4.06M | 3.10M | 2.51M | 2.34M | 2.06M | 2.01M | 1.91M | 1.78M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.92M | -$2.23M | -$3.00M | -$2.57M | -$2.36M | -$3.03M | -$4.65M | -$1.79M |
| Capital expenditure | — | — | — | $0 | $1,853 | $0 | $3,251 | — |
| Free cash flow | — | — | — | -$2.57M | -$2.36M | -$3.03M | -$4.65M | — |
| Investing cash flow | — | — | — | $0 | -$1,853 | $0 | -$3,251 | — |
| Financing cash flow | $2.58M | $2.31M | $1.30M | $2.72M | $648,355 | $1.26M | $1.97M | $7.45M |
| Depreciation & amortization | $400 | $504 | $555 | $555 | $401 | $401 | $5,517 | $407 |
| Stock-based compensation | $108,427 | $672,102 | $252,364 | $325,103 | $473,384 | $592,644 | $548,765 | $763,208 |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.